Biotherapeutic protein production is driven by cell line, cell culture media and supplementation, and bioprocess. While improvements in cell culture media and supplementation have enabled significant advancements in bioproduction titers, optimization to meet the specific needs of individual production cell lines continues to be a key factor to achieving desired production and protein quality. This is especially relevant to the ever increasing number of biosimilar therapeutics. Not only is it desirable to achieve a cost effective level of production, it…